DSIP (Delta Sleep-Inducing Peptide): Research Guide and Evidence Review
By UK Peptide Lab Research Team•22 May 2026•6 min read
What is DSIP?
Delta sleep-inducing peptide (DSIP) is a small 9-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of approximately 850 Da. It was originally isolated by Schoenenberger and Monnier from the cerebral venous blood of rabbits induced into delta-wave sleep, and characterised in publications in 1977. The peptide takes its name from the observation that intraventricular infusion produced enhancement of slow-wave (delta) and spindle EEG patterns in rabbit recipients.
DSIP is supplied for research use by UK Peptide Lab as lyophilised powder. The research literature on DSIP is unusual in that the peptide has been studied for nearly five decades without its precise mechanism, endogenous source, or physiological role being fully established.
Discovery and Original Research
Schoenenberger and Monnier reported the characterisation of DSIP in the Proceedings of the National Academy of Sciences in 1977. The peptide was isolated from cerebral venous blood collected from rabbits during electrically induced sleep, and the synthetic nonapeptide was shown to reproduce the original biological activity under double-blind conditions. A follow-up publication in Experientia the same year compared the synthetic and original nonapeptides directly. These early studies established DSIP as a candidate sleep-promoting factor and triggered substantial preclinical research interest through the 1980s and 1990s.
Mechanism: Largely Uncharacterised
In nearly five decades of research, no specific DSIP receptor has been cloned or definitively characterised. The peptide's mechanism remains largely a matter of inference from observed effects rather than direct receptor-binding evidence. Hypothesised mechanisms include modulation of the hypothalamic-pituitary-adrenal axis through interaction with corticotropin-releasing factor signalling, indirect effects on opioid system tone, and influence on sleep-wake regulatory circuits through unidentified targets.
Kovalzon and Strekalova published a review in the Journal of Neurochemistry in 2006 titled 'Delta sleep-inducing peptide (DSIP): a still unresolved riddle.' The review concluded that the hypothesis linking DSIP to sleep regulation remained extremely poorly documented despite the peptide's name, and proposed that a related but distinct natural DSIP-like peptide might be responsible for some of the biological activity observed in DSIP-immunoreactive tissue. The published literature has not resolved this question.
Research Applications
DSIP has been studied across a broad range of preclinical models including sleep research, stress and HPA-axis research, opioid system interaction research, and neuroprotection models. The peptide has also been examined in animal models of alcohol withdrawal and analgesia. Despite the breadth of preclinical literature, human clinical evidence is limited and largely confined to small uncontrolled studies from the 1980s and 1990s, with mixed and difficult-to-interpret results.
Evidence Base: A Cautionary Note
Researchers selecting DSIP as a tool should be aware that the evidence base is substantially weaker than that for other research peptides covered on this site. The mechanism is poorly characterised, the receptor is unidentified, and the link between the peptide and its eponymous biological activity remains contested in the published literature. DSIP is consequently most appropriate as a research compound for laboratories specifically investigating its disputed mechanism or comparing it to better-characterised neuropeptides, rather than as a tool for general neurological research where alternatives such as Semax or Selank have stronger published evidence bases. See the Semax vs Selank nootropic comparison for context on better-characterised neuropeptide research tools.
Laboratory Handling
DSIP is supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the inner wall of the vial and swirling gently. Never shake. Store the reconstituted solution at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles which compromise peptide integrity. See the peptide storage guide for detailed handling protocols.
Sourcing in the UK
UK Peptide Lab supplies research-grade DSIP as lyophilised powder with full third-party HPLC documentation published on the product page. Same-day UK dispatch on orders placed before 2pm GMT. For in-vitro laboratory research use only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.